How the FDA's Bulk Peptide Reclassification May Have Been Illegal - And Why It Matters for Your Access

If you have been trying to understand why so many peptides suddenly became hard to get, why your compounding pharmacy stopped carrying certain compounds, or why the telehealth clinic that was prescribing your protocol quietly pulled it from their menu - the FDA is the short answer. In September 2023, the agency moved approximately 19 peptides into a restricted category in a single administrative sweep. It used a process that its own written rules say it is not supposed to use.

That action was bulk, simultaneous, and apparently without the individualized safety analysis the agency's own guidance requires. It is now being challenged, partly reversed, and scrutinized by regulatory attorneys and compounding pharmacy trade groups who argue it was procedurally deficient from the start. The compounds did not become more dangerous; the agency simply acted in a way that may not have been lawful, and the consequences landed on patients, providers, researchers, and the entire compounding ecosystem.

This is that story.

First, Get the Terminology Right - This Is Not DEA Scheduling

When the "peptides are now Schedule 2" panic spreads through online health communities, the framing is flatly wrong, and understanding why is the first step to understanding what actually happened.

The FDA did not reclassify these peptides as Schedule II controlled substances under the Controlled Substances Act. DEA scheduling - the system that governs opioids, stimulants, and similar drugs - is a different legal framework entirely, run by a different agency.

What actually happened lives inside a narrower regulatory system called the compounding bulk drug substance framework, created by the Drug Quality and Security Act (DQSA) and governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Under Section 503A, traditional compounding pharmacies can prepare drugs for individual patients based on a specific prescription. Those compounded drugs are generally exempt from FDA's normal premarket approval process. That exemption is the foundation of compounding - it is why a pharmacy can mix a customized hormone cream or prepare a peptide injection for a specific patient without running a full clinical trial program.

But there is a catch. Because compounded drugs skip premarket approval, FDA created a separate list-making system to manage which bulk drug substances pharmacies are allowed to use as starting material. Substances fall into one of two categories:

Category 1 - substances that are nominated for compounding use and are under evaluation or already approved for that use.

Category 2 - substances that FDA has determined "raise significant safety risks" for compounding. Pharmacies operating under 503A cannot use these as bulk starting material.

Category 2 is the restriction mechanism. It is not DEA scheduling. It is not a controlled substance designation. But practically speaking, for a compounding pharmacy, placement in Category 2 has the same effect as prohibition - you cannot legally use it in a patient prescription.

FDA's live compounding page, titled "Certain Bulk Drug Substances Used in Compounding May Present Significant Safety Risks," maintains the category table with exact dates substances were added.

The September 2023 FDA Peptide Reclassification - What Actually Happened

Imagine logging in to refill your peptide prescription in October 2023 and being told your pharmacy can no longer fill it. Not because the compound became dangerous overnight. Not because new science emerged. Because an administrative category changed - and nobody voted on it.

On September 29, 2023, the FDA added multiple peptides to its 503A Category 2 list. The substances confirmed in FDA's own category table include GHRP-2 (Growth Hormone Releasing Peptide-2), GHRP-6 (Growth Hormone Releasing Peptide-6), ipamorelin acetate, and kisspeptin-10. Secondary regulatory reporting describes the broader late-2023 cycle as encompassing approximately 19 peptides in total, though the exact full list of all 19 comes from secondary sources rather than a single confirmed primary FDA document. The four substances named above are confirmed by FDA's primary category table; the remainder of the approximately 19 total are referenced in secondary regulatory reporting.

The effect was immediate and concrete. Compounding pharmacies that had been legally preparing these peptides for patients under Section 503A were no longer permitted to do so. Prescribers who relied on compounded versions - often because no FDA-approved commercial product existed for the same clinical application - lost that option. Patients, researchers, and telehealth users who had been accessing compounded BPC-157 for gut healing, ipamorelin for growth hormone support, or TB-500 for recovery found their prescriptions could no longer be filled.

Here is what makes the timing significant: this was not a rolling process where the agency worked through its list one compound at a time over several months. Approximately 19 chemically distinct substances, with different molecular structures, different mechanisms, different evidence profiles, and different histories of use, were moved into Category 2 in what appears to have been a single coordinated action.

That is the procedural problem.

FDA's Own Rules Require Substance-by-Substance Peptide Access Review - And That Is the Core Problem

The honest answer is that FDA broke its own rules - or at least departed from them so sharply that it is hard to characterize what happened as anything else.

FDA's own guidance document on the 503B bulk drug substance framework states explicitly that the agency "intends to conduct a balancing test" on a substance-by-substance basis before making inclusion or exclusion decisions. The four factors the agency says it will weigh individually for each nominated substance are:

1. Physical and chemical characterization of the substance
2. Safety issues specific to that substance
3. Evidence of effectiveness or lack of effectiveness
4. Whether there is a clinical need to compound from the bulk substance rather than from an existing FDA-approved product

That fourth factor - clinical need - is particularly important. FDA's position is that it generally finds no clinical need unless the nominator can demonstrate that a drug product must be produced from the bulk substance rather than from an approved commercial alternative. In other words, if there is already an approved drug that serves the same purpose, FDA can say there is no clinical need for a compounded version.

The problem with applying that logic to peptides like BPC-157 or TB-500 is that no FDA-approved commercial alternatives exist. These are not generic versions of branded drugs. They are peptide compounds that patients, researchers, and telehealth users were accessing through compounding specifically because there was no approved commercial product. The "clinical need" analysis, if applied honestly and individually to each compound, would have to grapple with that reality.

Critics of the September 2023 action argue that moving approximately 19 substances simultaneously suggests the agency did not perform that individualized analysis for each one. If it had, the four-factor balancing test would have produced different records, different timelines, and potentially different outcomes for different compounds. A simultaneous bulk action looks less like individualized review and more like a policy decision applied categorically to a class of substances.

That distinction matters under federal administrative law.

The APA Argument in the FDA Peptide Reclassification - Why "Arbitrary and Capricious" Has Real Teeth

The Administrative Procedure Act (APA) - the federal law that sets the rules agencies must follow when making decisions - prohibits agency action that is "arbitrary and capricious" (meaning the agency acted without a rational reason or ignored its own rules), "an abuse of discretion, or otherwise not in accordance with law." That phrase sounds like legal boilerplate, but courts have used it repeatedly to strike down exactly the kind of procedural shortcut the September 2023 action appears to represent.

Here is how it applies.

Failure to follow agency guidance. If the agency's own published guidance commits it to an individualized balancing test and the September 2023 action was made without performing that test for each compound, a reviewing court could find that the agency departed from its own stated methodology without explanation. Agencies are allowed to change their procedures - but they have to explain why. Unexplained departures from established procedure are a classic basis for an "arbitrary and capricious" finding.

Inadequate notice and reasoning. APA challenges also arise when an agency acts without providing adequate reasoning for its decision. The administrative record - the documented evidence and analysis the agency relied on when making its decision, which a reviewing court later examines - must contain individualized safety analyses for each affected substance. If it does not contain individualized safety analyses for each of the 19 affected substances, that gap could support a challenge.

Contrary to the statute. The DQSA created the framework FDA is using. If FDA's categorical approach exceeded what the statute actually authorizes - if Congress created a process for individual evaluation and FDA substituted a bulk action - a court could find the agency acted contrary to law.

Unreasonable delay or failure to complete rulemaking. The broader pattern of FDA not finalizing its bulk-substance lists has itself been litigated. The OFA settlement discussed below is evidence that the agency agreed - under legal pressure - that it had obligations it was not meeting.

None of this means a court has ruled the September 2023 action illegal. No ruling to that effect exists yet. What it means is that the legal theory is well-established and has been successfully used against FDA's compounding decisions before. The September 2023 peptide action sits squarely in that legal territory.

Legal Challenges to FDA Peptide Reclassification - Who Sued and What They Argued

FDA has already been taken to court multiple times over exactly this kind of procedural failure in the compounding space, and it has lost or settled. The legal tools those plaintiffs used are still available.

The legal landscape around FDA's compounding bulk-substance decisions predates September 2023. Several cases have tested the boundaries of the agency's authority in this area, and together they sketch the legal framework that critics of the peptide reclassification are working within.

Par Sterile Products and Endo Par Innovation v. FDA

Par Sterile Products LLC and Endo Par Innovation Company LLC filed suit challenging FDA's 503B interim policy and the agency's failure to promulgate - formally adopt through the required rulemaking process - a binding bulk-substances list. The complaint advanced the legal theory that FDA acted contrary to law and in violation of the APA by allowing compounding of nominated substances without proper statutory limits. The suit specifically pointed to vasopressin as a compound being compounded in ways the plaintiffs argued were unlawful. This case illustrates the APA framework being applied directly to FDA's bulk-substance list process.

Athenex v. FDA

After FDA excluded vasopressin from the 503B bulks list, Athenex filed a separate lawsuit. Its complaint advanced an APA and contrary-to-law argument: that FDA had unlawfully considered the existence of the approved drug Vasostrict when assessing clinical need for the bulk substance. This case is important because it directly challenges how FDA applies the "clinical need" standard - the same standard that is supposed to be applied individually to each peptide before it is placed in Category 2. If the clinical-need analysis can be misapplied in one direction (for exclusion), it can be misapplied in another (for restriction), and the legal theory transfers.

Outsourcing Facilities Association v. FDA

The Outsourcing Facilities Association (OFA) - the trade group representing FDA-registered 503B outsourcing facilities - sued FDA over its handling of the entire bulk-drug-substance review process. The OFA argued the agency had delayed or improperly managed required review and listing obligations. The case reached a settlement in 2022. Under its terms, FDA committed to promptly reviewing long-pending nominations for active pharmaceutical ingredients used by 503B facilities - an obligation the agency had not been meeting until outside legal pressure forced the issue.

That settlement is significant in ways that extend beyond the case itself. It is an official acknowledgment - agreed to by FDA - that the agency had obligations under the statute it was not meeting, and that outside legal pressure was required to get the agency to commit to meeting them. When critics of the September 2023 action point to FDA's pattern of procedural shortcuts in the compounding space, the 2022 OFA settlement is one of their strongest supporting data points.

Consumer Class Actions

A separate category of consumer-facing lawsuits uses state consumer-protection claims to allege that products are unlawfully classified. Courts have generally resolved these by applying the primary jurisdiction doctrine - a principle under which courts defer to the relevant federal agency to resolve the underlying regulatory classification question before adjudicating the consumer claim. That approach has the practical effect of slowing resolution and keeping patients and researchers in legal limbo while the regulatory process plays out.

The full litigation picture shows a consistent pattern: FDA's management of the compounding bulk-substance framework has been legally contested, the agency has lost or settled multiple challenges, and the legal theories available for challenging the September 2023 peptide action are well-established and have succeeded before.

What Patients, Providers, and Researchers Lost to FDA Peptide Reclassification

Think about what it actually means when your prescription disappears - not because the compound became dangerous, but because a federal agency changed an administrative category. That is not a hypothetical. That is what happened to thousands of patients in October 2023.

The human stakes - lost prescriptions, no approved alternatives, and a gray market that grew to fill the gap - are what turn a procedural argument into a patient-access crisis. Here is what the September 2023 action meant in practice for everyone caught in the middle.

Compounding pharmacies lost the ability to fill legal prescriptions. Pharmacies operating under Section 503A could no longer use the restricted peptides as bulk drug substances. A prescription written by a licensed physician for a patient with a specific clinical need could not be filled. Not because the compound had become more dangerous. Because the administrative category had changed.

Providers lost a clinical tool with no approved replacement. For peptides like BPC-157, ipamorelin, and TB-500, there is no FDA-approved commercial drug that patients can purchase at a pharmacy. The compounded version was often the only legal avenue for providers, patients, and telehealth platforms alike. When compounding was restricted, the option did not shift to an approved alternative - it disappeared.

Patients absorbed real cost. Compounded peptides are generally significantly less expensive than any commercial pharmaceutical equivalent in adjacent categories. Patients who had been managing recovery, metabolic health, or hormonal support through compounded protocols faced either stopping entirely or turning to gray-market suppliers with no regulatory oversight - a safety outcome that is the precise opposite of what the Category 2 framework is supposed to achieve.

Researchers and telehealth platforms faced legal exposure. Providers prescribing compounded peptides through telehealth platforms suddenly faced the question of whether a prior prescription could still be filled. Many clinics proactively pulled peptide protocols from their offerings. Not because the science changed. Because the regulatory risk calculation changed. The chilling effect on prescribers, researchers, and telehealth operators was substantial.

The gray market expanded. Here is the darkest irony of the September 2023 action: by restricting access through licensed compounding pharmacies - the regulated, inspected, accountable part of the supply chain - FDA effectively pushed more demand toward unregulated research-chemical suppliers where there is no oversight at all. If the goal was patient safety, the actual outcome moved in the opposite direction.

The 2026 Reversal - What It Implies About the Original FDA Peptide Reclassification

In April 2026, FDA began unwinding some of the September 2023 restrictions. A Federal Register notice published April 16, 2026 announced that certain peptide substances were being removed from Category 2 and moved into an advisory committee review path. The formal effective date for removal of affected peptides was April 23, 2026. That same notice announced a scheduled Pharmacy Compounding Advisory Committee (PCAC) meeting for July 2026.

The GHK-Cu case illustrates the procedural instability most clearly. GHK-Cu - the copper peptide - was removed from Category 1 on April 22, 2026 after nominators withdrew their nominations. FDA stated it would be added back to Category 1 for non-injectable routes after clarification. FDA's nominated substances document, updated May 14, 2026, documents this back-and-forth in detail. A compound moved, then moved back, based on nomination paperwork rather than new safety science is a compound whose original placement was not built on a stable evidentiary foundation.

Seven peptides are scheduled for PCAC review at the July 2026 meeting: BPC-157, KPV, TB-500, MOTs-C, Emideltide (also known as DSIP), Semax, and Epitalon. Five additional peptides - GHK-Cu, Melanotan II, cathelicidin (LL-37), Dihexa acetate, and PEG-MGF - are planned for a second PCAC meeting by the end of February 2027.

Here is what that sequence tells you about the original 2023 action.

The PCAC review process - an advisory committee of outside experts who evaluate evidence and make recommendations - is being used now, on the back end, to decide whether restrictions should be lifted. If that process is appropriate for deciding whether to remove restrictions, the obvious question is: why was it not used before restrictions were imposed? The April 16, 2026 Federal Register notice initiating this review path implicitly answers that question. It was not used. The restoration process is effectively doing the individualized review that should have happened in 2023.

Reading between the lines of the April 2026 Federal Register notice: the agency is now building the evidentiary record for these substances that critics argue should have been built before they were placed in Category 2.

A reversal is not an admission of wrongdoing under administrative law. But a reversal, combined with a new process that looks like the procedure the original action skipped, is about as close to an implicit concession as a federal agency typically comes.

What a Procedurally Correct FDA Peptide Reclassification Process Would Look Like

Understanding what went wrong is easier when you know what right looks like.

Under FDA's own 503B bulk-substance guidance, the process for evaluating a nominated substance is supposed to work like this: a nominator submits the substance with supporting documentation. FDA evaluates the four-factor balancing test for that specific compound - chemical characterization, safety profile, evidence of effectiveness, and clinical need. If the agency has questions or needs more information, it requests additional data through the nomination process rather than defaulting to categorical restriction. If the substance warrants advisory committee review, the PCAC evaluates the evidence and makes a recommendation. FDA then makes a final determination for that substance on the record.

The key features of that process are its individuality and its transparency. Each compound gets its own analysis. The administrative record - the documented evidence and reasoning behind the decision - is built for each compound separately. The reasoning is documented. If a court later reviews the decision, there is a record to review.

Applied to the September 2023 action, the procedurally correct approach would have meant evaluating each of the approximately 19 peptides separately, building individual records showing the safety concerns specific to each compound, documenting the clinical-need analysis for each one, and - where expert review was appropriate - running each compound through PCAC before restricting access rather than after.

That process would have taken longer. Some compounds might still have ended up in Category 2 after proper individual review. But the decisions would have been on solid legal ground, and patients, providers, researchers, and anyone trying to access peptides legally would have had the transparency to understand why each compound was treated the way it was.

The irony is that FDA's own 503A interim policy - which governed newly nominated substances through January 7, 2025 - was not designed for bulk categorical action. It was designed for the kind of case-by-case evaluation that the September 2023 action apparently bypassed.

How the FDA Peptide Reclassification - Not the Compounds - Created the Gray Area

Here is what the FDA does not want you to connect: the gray-area reputation that surrounds peptides right now is not a reflection of the science. It is the downstream effect of a regulatory action that may not have followed the agency's own rules. You are navigating a landscape made more confusing, more dangerous, and more inaccessible specifically because of a procedural shortcut a federal agency took.

There is a common misconception that peptides occupy a regulatory gray area because they are inherently ambiguous - compounds that fall between categories, neither clearly drugs nor clearly supplements, operating in a space where the science is uncertain and the rules are unclear. That framing misidentifies the cause. Getting the cause wrong means consumers, providers, and researchers cannot advocate effectively for their own access.

Peptides are not in a gray area because of anything inherent about peptides. They are in a gray area because FDA took an action that may have been procedurally improper, created a regulatory consequence that blocked legitimate access, and left patients, providers, researchers, and the market scrambling to adapt. The gray area was manufactured by the reclassification, not by the compounds.

Before September 2023, a licensed physician could write a prescription for compounded BPC-157 or ipamorelin, and a licensed compounding pharmacy could fill it. That is a regulated, legal supply chain operating under FDA oversight - not a gray area. The Category 2 placement disrupted that supply chain without providing a legal alternative, and the resulting vacuum is what produced the gray area.

This matters for how health-conscious adults should think about their own situation. The compounds themselves have not been found dangerous. FDA's own rationale for Category 2 placement is not that these peptides caused documented harm at scale - it is that they lack the evidence package that fully approved drugs carry. That is a different claim. Many compounded medications lack full approval evidence and are prescribed every day; the 503A exemption exists precisely to allow that. The question is whether FDA's specific decision to treat these peptides as categorically ineligible for compounding was procedurally sound.

Legal advocates and compounding pharmacy trade groups argue consistently that the answer is no - and that the people paying the price for FDA's procedural shortcut are the patients, providers, researchers, and anyone trying to access compounds with legitimate wellness and clinical applications.

The message that practitioners were hearing from patients changed after September 2023 not because the science changed but because access changed. Patients who had been benefiting from compounded peptide protocols suddenly found those protocols unavailable. Providers who wanted to continue prescribing them faced legal and reputational risk. The ripple effects through the telehealth and compounding pharmacy ecosystems were not a response to new evidence about these compounds - they were a response to a regulatory action whose procedural validity is now being contested.

What Advocates and Legal Experts Are Saying About Restoring Peptide Access

The picture in mid-2026 is more encouraging than the situation looked in late 2023, but the outcome is not settled.

The PCAC review schedule for July 2026 - covering BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, and Epitalon - represents a genuine pathway toward restored compounding access for these compounds. PCAC review is the process required before substances can be included on the 503A bulk drug substances list. If the committee recommends inclusion and FDA agrees, compounding pharmacies could once again legally prepare these peptides for patients, providers, and telehealth users who need them.

The second wave of reviews planned for by February 2027 - GHK-Cu, Melanotan II, cathelicidin (LL-37), Dihexa acetate, and PEG-MGF - extends that pathway to a broader set of compounds.

Regulatory attorneys who have tracked the litigation history argue that the 2022 OFA settlement has already established that FDA has enforceable procedural obligations in the bulk-substance space. If FDA fails to complete the PCAC reviews on schedule or takes actions that again appear to bypass individualized analysis, the legal tools for challenging those actions are established and have worked before.

The compounding pharmacy community's position - reflected in the OFA litigation and subsequent settlement - is not that FDA has no authority to restrict compounding. It is that the authority must be exercised in accordance with the statutory framework and the agency's own guidance. A bulk action that sweeps approximately 19 chemically distinct compounds into a restricted category in a single day does not look like that kind of individualized exercise of authority.

A Federal Register notice published May 1, 2026, titled "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B," signals that FDA is continuing to build its formal list-making process in a way that is more consistent with its stated methodology. That is progress - but it is progress that is happening partly because outside legal pressure made the alternative legally untenable.

For patients, providers, researchers, and anyone watching this space, the practical message is this: the PCAC review process is the mechanism to watch. July 2026 and the months following will determine whether the seven compounds scheduled for review gain a pathway back into legitimate compounding. The outcomes of those reviews - and whether FDA follows through on its stated process - will tell you more about where this is headed than any single press release or regulatory filing.

Frequently Asked Questions About the FDA Peptide Reclassification

Did the FDA make peptides illegal to use?

No. The FDA's Category 2 classification restricts licensed compounding pharmacies from using certain peptides as bulk drug substances when preparing prescriptions under Section 503A. It does not make possession or personal use of these compounds illegal under federal law, and it is entirely separate from DEA controlled-substance scheduling. The practical effect is that obtaining these compounds through the regulated, prescription-based compounding pathway became much more difficult or impossible for patients, providers, and researchers who relied on it.

Why did FDA restrict so many peptides at once instead of reviewing them individually?

That is the core question driving the legal challenges. FDA's own guidance commits the agency to a substance-by-substance balancing test before placing bulk drug substances in Category 2. Moving approximately 19 chemically distinct compounds in what appears to have been a single action does not, on its face, look like individualized review. Critics argue the bulk approach was procedurally deficient, and the 2026 partial reversal - which is now performing the individual reviews retroactively through PCAC - appears to support that reading.

What is a PCAC review and why does it matter for peptide access?

PCAC stands for Pharmacy Compounding Advisory Committee - an FDA advisory body that evaluates evidence on bulk drug substances and makes recommendations about whether they should be eligible for compounding. PCAC review is required before substances can be included on the 503A bulk drug substances list. Seven peptides are scheduled for PCAC review in July 2026, and positive recommendations from that committee would create a pathway for those compounds to return to legal compounding access for patients, providers, and telehealth users.

If the FDA action was procedurally improper, why haven't courts stopped it?

Challenging federal agency action in court is a slow process. APA challenges require building an administrative record, filing in federal court, and working through a legal timeline that often spans years. The litigation challenging earlier FDA compounding decisions - the OFA case, the Par Sterile Products case, the Athenex case - each took years to resolve. The September 2023 action is recent enough that litigation challenging it specifically may still be working through early stages, or the 2026 reversal process may have partially mooted some of the most immediate claims.

Which specific peptides are being reviewed for potential restoration in 2026 and 2027?

The July 2026 PCAC review covers BPC-157, KPV, TB-500, MOTs-C, Emideltide (also called DSIP), Semax, and Epitalon. A second PCAC review planned for by the end of February 2027 covers GHK-Cu, Melanotan II, cathelicidin (LL-37), Dihexa acetate, and PEG-MGF. Positive PCAC recommendations for any of these compounds would not automatically restore compounding access, but would represent a significant step in that direction if FDA follows through on its stated process.

Is this situation unique to the US, or are other countries dealing with the same issue?

The 503A and 503B compounding framework is specific to the United States and the Federal Food, Drug, and Cosmetic Act. Other countries have their own regulatory approaches to peptide compounding and prescribing. The challenges described in this article - bulk categorical restriction, the procedural argument, the litigation - are specifically about how US law and FDA administrative procedure interact. International availability of specific peptides varies significantly by country and regulatory context.

What made September 2023 different from earlier FDA-compounding friction was the scale and speed - and the apparent departure from the individualized process the agency's own guidance requires. The 2026 reversal is not a clean resolution. It is an acknowledgment that the original action left unfinished business, and the PCAC process is the mechanism now being used to finish it. Whether that process moves quickly enough, covers all the right compounds, and produces outcomes consistent with what the evidence supports - that is what the next eighteen months will reveal.